ethyl 1,4-dibenzyl-1,4-diazepane-2-carboxylate | 847556-35-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 1,4-dibenzyl-1,4-diazepane-2-carboxylate
• 英文别名: Ethyl 1,4-bis(phenylmethyl)-1,4-diazepane-2-carboxylate
• CAS: 847556-35-8
• 化学式: C₂₂H₂₈N₂O₂
• 分子量: 352.477
• InChiKey: WBPLFGZLXPQFKC-UHFFFAOYSA-N

物化性质

• 沸点：
  451.5±45.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 1,4-dibenzyl-1,4-diazepane-2-carboxylate 在 palladium on activated charcoal 吡啶 、 盐酸 、 sodium hydroxide 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-(4-But-2-ynyloxy-benzenesulfonyl)-4-methyl-[1,4]diazepane-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors

  摘要：

  Potent and selective TACE and MMP inhibitors utilizing the diazepine and thiazepine ring systems were synthesized and evaluated for biological activity in in vitro and in vivo models of TNF-α release. Oral activity in the mouse LPS model of TNF-α release was seen. Efficacy in the mouse collagen induced arthritis model was achieved with diazepine 20. © 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.053
• 作为产物：
  描述：

  苯甲醛 在 对甲苯磺酸 、 N,N-二异丙基乙胺 作用下， 以 苯 为溶剂， 反应 3.0h， 生成 ethyl 1,4-dibenzyl-1,4-diazepane-2-carboxylate
  参考文献：
  名称：

  [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
  [FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTERNE RÉNAL

  摘要：

  公开号：

  WO2014099633A3

文献信息

• Bicyclic piperazine compound and use thereof
  申请人：Fukatsu Kohji

  公开号：US20070072865A1

  公开（公告）日：2007-03-29

  The present invention provides a compound represented by the formula: wherein R 1 is an acyl group, R 2 is a hydrocarbon group which may be substituted or the like, R 3 is a hydrocarbon group which may be substituted or the like, R 4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, a sulfur atom or the like, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.

  本发明提供一种化合物，其化学式为：其中，R1是酰基，R2是烃基，可以被取代或类似物，R3是烃基，可以被取代或类似物，R4是烃基，可以被取代或类似物，n为0至4，X为氧原子、硫原子或类似物或其盐。本发明还提供一种具有TGR23拮抗活性的化合物，因此可用于预防和治疗癌症。
• Bicyclic piperazine compound having TGR23 antagonistic activity
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07795267B2

  公开（公告）日：2010-09-14

  The present invention provides a compound represented by the formula: wherein R1 is —(C═O)—NR7R8 or —(C═O)—OR6, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.

  本发明提供了一种化合物，其表示为以下公式：其中R1为—（C═O）—NR7R8或—（C═O）—OR6，R2为可取代或类似的烃基，R3为可取代或类似的烃基，R4为可取代或类似的烃基，n为0至4，X为氧原子或其盐。本发明还提供了一种具有TGR23拮抗活性的化合物，因此可用于预防和治疗癌症。
• Inhibitors of the Renal Outer Medullary Potassium Channel
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150329557A1

  公开（公告）日：2015-11-19

  The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

  本发明提供了I式化合物及其药学上可接受的盐，它们是ROMK（Kir1.1）通道的抑制剂。这些化合物可用作利尿剂和/或钠利尿剂，并用于治疗和预防包括高血压、心力衰竭和与过度盐和水潴留有关的医疗条件在内的心血管疾病。
• BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1661898A1

  公开（公告）日：2006-05-31

  The present invention provides a compound represented by the formula: wherein R1 is an acyl group, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, a sulfur atom or the like, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.

  本发明提供了一种由式表示的化合物： 其中 R1 是酰基，R2 是可被取代的烃基或类似物，R3 是可被取代的烃基或类似物，R4 是可被取代的烃基或类似物，n 是 0 至 4，X 是氧原子、硫原子或类似物，或其盐。本发明还提供了一种化合物，它具有 TGR23 拮抗剂活性，因此可用于预防和治疗癌症。
• EP1661898
  申请人：——

  公开号：——

  公开（公告）日：——